Author

N. Thebault

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

E. Darbo· 2 shared F. Chibon· 2 shared G. Perot· 2 shared J.-Y. Blay· 2 shared L. Darmusey· 2 shared L. Gaston· 2 shared L. Leroy· 2 shared N. Desplat· 2 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Darbo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Distinct cellular origins and differentiation process account for distinct oncogenic and clinical behaviors of leiomyosarcomas

E. Darbo, G. Perot, L. Darmusey, S. Le Guellec, L. Leroy, L. Gaston, N. Desplat, N. Thebault, C. Merle, P. Rochaix, T. Valentin, G. Ferron, C. Chevreau, B. Bui, E. Stoeckle, , F. Chibon

The paper identifies a transcriptionally homogeneous subgroup of leiomyosarcomas originating from vascular smooth muscle cells and explains their unique oncogenic behavior through specific pathway alterations.

bioRxiv · Oct 23, 2020Cancer Biology

ATRX alteration contributes to tumor growth and immune escape in pleomorphic sarcomas

L. Darmusey, G. Perot, N. Thebault, S. Le Guellec, N. Desplat, L. Gaston, L. Delespaul, T. Lesluyes, E. Darbo, A. Gomez-Brouchet, E. Richard, J. Baud, L. Leroy, J. M. Coindre, J.-Y. Blay, F. Chibon

This study shows ATRX mutations in sarcomas promote tumor growth and immune escape by reducing mast cell immunity, suggesting targeting the innate immune system could improve outcomes.

bioRxiv · Oct 23, 2020Cancer Biology